Recent Updates
Recently added Catalysts

ADH300004

Phase 1

Neoplasms | Small molecule | Oncology |Fennec Pharmaceuticals Inc.|Last Updated: Aug 6, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00264446A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic ResectionPHASE1 COMPLETED - - -Aug 6, 20071 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
ADH300004DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range19 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Signed written informed consent * \> or = 19 years of age * Patients with histologically confirmed: * primary or metastatic (known or suspected) colorectal carcinoma requiring planned surgical resection with hepatic biopsy and systemic chemotherapy , or * primary or metas...

Countries:United States
Unlock Eligibility Criteria